Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $4.39, but opened at $4.50. Recursion Pharmaceuticals shares last traded at $4.46, with a volume of 7,352,805 shares changing hands.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.60.
Check Out Our Latest Research Report on RXRX
Recursion Pharmaceuticals Stock Down 5.6%
The business's fifty day moving average price is $4.91 and its 200 day moving average price is $6.41. The company has a market capitalization of $1.71 billion, a P/E ratio of -2.75 and a beta of 0.99. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.39) earnings per share. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in RXRX. Barclays PLC lifted its holdings in shares of Recursion Pharmaceuticals by 53.9% during the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock worth $4,596,000 after acquiring an additional 244,278 shares during the period. Brighton Jones LLC lifted its holdings in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Recursion Pharmaceuticals by 101.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 50,761 shares of the company's stock valued at $343,000 after purchasing an additional 25,579 shares during the last quarter. KBC Group NV lifted its holdings in Recursion Pharmaceuticals by 61.9% during the 4th quarter. KBC Group NV now owns 12,307 shares of the company's stock valued at $83,000 after purchasing an additional 4,705 shares during the last quarter. Finally, Institute for Wealth Management LLC. bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $3,928,000. 89.06% of the stock is owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
